MT-3724 is Molecular Templates’ lead drug candidate. MT-3724 is currently in Phase 1 clinical trials at the Memorial Sloan-Kettering Cancer Center, the MD Anderson Cancer Center, the Lineberger Comprehensive Cancer Center at the University of North Carolina, and the University of Arizona. The Phase 1 study is enrolling relapsed and refractory non-Hodgkin’s lymphoma (NHL) patients. More information on the Phase 1 study is available at clinicaltrials.gov.
MT-3724 is an immunotoxin that targets the CD20 cell surface antigen present in a variety of lymphomas and leukemias. Upon binding to the CD20 antigen, MT-3724 induces its own internalization into the target cell. Once inside the cell, MT-3724 self-routes to the cytosol where it enzymatically and permanently shuts down ribosome function thereby directly killing the cell. This represents a unique mechanism of action in oncology. Clinical data have shown activity in patients whose disease has progressed or was not responsive to chemotherapy and Rituxan.
MT-3724 is a first-generation ETB; it is not fully de-immunized.